Giuseppe De Luca1, Miha Cercek2, Lisette Okkels Jensen3, Marija Vavlukis4, Lucian Calmac5, Tom Johnson6, Gerard Roura I Ferrer7, Vladimir Ganyukov8, Wojtek Wojakowski9, Clemens von Birgelen10, Francesco Versaci11, Jurrien Ten Berg12, Mika Laine13, Maurits Dirksen14, Gianni Casella15, Petr Kala16, José Luis Díez Gil17, Victor Becerra18, Ciro De Simone19, Xavier Carrill20, Alessandra Scoccia21, Arpad Lux22, Tomas Kovarnik23, Periklis Davlouros24, Gabriele Gabrielli25, Xacobe Flores Rios26, Nikola Bakraceski27, Sébastien Levesque28, Vincenzo Guiducci29, Michał Kidawa30, Lucia Marinucci31, Filippo Zilio32, Gennaro Galasso33, Enrico Fabris34, Maurizio Menichelli35, Stephane Manzo36, Gianluca Caiazzo37, Jose Moreu38, Juan Sanchis Forés39, Luca Donazzan40, Luigi Vignali41, Rui Teles42, Francisco Bosa Ojeda43, Heidi Lehtola44, Santiago Camacho-Freiere45, Adriaan Kraaijeveld46, Ylitalo Antti47, Marco Boccalatte48, Iñigo Lozano Martínez-Luengas49, Bruno Scheller50, Dimitrios Alexopoulos51, Giuseppe Uccello52, Benjamin Faurie53, Alejandro Gutierrez Barrios54, Bor Wilbert12, Giuliana Cortese55, Raul Moreno56, Guido Parodi57, Elvin Kedhi58, Monica Verdoia59,60. 1. Division of Cardiology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Università del Piemonte Orientale, Novara, Italy. giuseppe.deluca@med.uniupo.it. 2. Centre for Intensive Internal Medicine, University Medical Centre, Ljubljana, Slovenia. 3. Division of Cardiology, Odense Universitets Hospital, Odense, Danemark. 4. University Clinic for Cardiology, Medical Faculty, Ss' Cyril and Methodius University, Skopje, North Macedonia. 5. Clinic Emergency Hospital of Bucharest, Bucharest, Romania. 6. Division of Cardiology, Bristol Heart Institute, University Hospitals Bristol, NHSFT & University of Bristol, Bristol, UK. 7. Interventional Cardiology Unit, Heart Disease Institute, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain. 8. Division of Cardiology, State Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo,, Russia. 9. Division of Cardiology, Medical University of Silezia, Katowice, Poland. 10. Department of Cardiology, Medisch Spectrum Twente, Thoraxcentrum Twente, Enschede, The Netherlands. 11. Division of Cardiology, Ospedale Santa Maria Goretti, Latina, Italy. 12. Division of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands. 13. Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 14. Division of Cardiology, Northwest Clinic, Alkmaar, The Netherlands. 15. Division of Cardiology, Ospedale Maggiore, Bologna, Italy. 16. University Hospital Brno, Medical Faculty of Masaryk University Brno, Brno, Czech Republic. 17. H. Universitario y Politécnico La Fe, Valencia, Spain. 18. Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain. 19. Division of Cardiology, Clinica Villa dei Fiori, Acerra, Italy. 20. Hospital Germans Triasi Pujol, Badalona, Spain. 21. Division of Cardiology, Ospedale "Sant'Anna", Ferrara, Italy. 22. Maastricht University Medical Center, Maastricht, The Netherlands. 23. University Hospital Prague, Prague, Czech Republic. 24. Invasive Cardiology and Congenital Heart Disease, Patras University Hospital, Patras, Greece. 25. Interventional Cardiology Unit, Azienda Ospedaliero Universitaria "Ospedali Riuniti", Ancona, Italy. 26. Complexo Hospitaliero Universitario La Coruna, La Coruna, Spain. 27. Center for Cardiovascular Diseases, Ohrid, North Macedonia. 28. Center Hospitalier, Universitaire de Poitiers, University Hospital, Poitiers, France. 29. AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy. 30. Central Hospital of Medical University of Lodz, Łódź, Poland. 31. Division of Cardiology, AziendaOspedaliera "Ospedali Riuniti Marche Nord", Pesaro, Italy. 32. Ospedale Santa Chiara di Trento, Trento, Italy. 33. Division of Cardiology, Ospedale San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy. 34. Azienda Ospedaliero - Universitaria Ospedali Riuniti Trieste, Trieste, Italy. 35. Division of Cardiology, Ospedale "F. Spaziani, Frosinone, Italy. 36. Division of Cardiology, CHU Lariboisière, AP-HP, Paris VII University, INSERM UMRS 942, Paris, France. 37. Division of Cardiology, Ospedale "G Moscati", Aversa, Italy. 38. Division of Cardiology, Complejo Hospitalario de Toledo, Toledo, Spain. 39. Division of Cardiology, Hospital Clinico Universitario de Valencia, Valencia, Spain. 40. Division of Cardiology, Ospedale "S. Maurizio" Bolzano Ospedale "S. Maurizio",, Bolzano, Italy. 41. Interventional Cardiology Unit, Azienda Ospedaliera Sanitaria, Parma, Italy. 42. Division of Cardiology, Hospital de Santa Cruz, CHLO - Carnaxide, Carnaxide, Portugal. 43. Division of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. 44. Division of Cardiology, Oulu University Hospital, Oulu, Finland. 45. Division of Cardiology, Juan Ramon Jimenez Hospital, Huelva, Spain. 46. Division of Cardiology, UMC Utrecht, Utrecht, The Netherlands. 47. Division of Cardiology, Heart Centre Turku, Turku, Finland. 48. Division of Cardiology, Ospedale Santa Maria delle Grazie, Pozzuoli, Italy. 49. Division of Cardiology, Hospital Cabueñes, Gijon, Spain. 50. Division of Cardiology, Clinical and Experimental Interventional Cardiology, University of Saarland, Saarbrücken, Germany. 51. Division of Cardiology, Attikon University Hospital, Athens, Greece. 52. Division of Cardiology, Ospedale "A. Manzoni" Lecco, Lecco, Italy. 53. Division of Cardiology, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France. 54. Division of Cardiology, Hospital Puerta del Mar, Cadiz, Spain. 55. Department of Statistical Sciences, University of Padova, Padova, Italy. 56. Division of Cardiology, Hospital la Paz, Madrid, Spain. 57. Azienda Ospedaliero-Universitaria Sassari, Sassari, Italy. 58. Division of Cardiology, St-Jan Hospital, Brugge, Belgium. 59. Division of Cardiology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Università del Piemonte Orientale, Novara, Italy. 60. Division of Cardiology, Ospedale degli Infermi, ASL Biella, Ponderano, Italy.
Abstract
BACKGROUND: It has been suggested the COVID pandemic may have indirectly affected the treatment and outcome of STEMI patients, by avoidance or significant delays in contacting the emergency system. No data have been reported on the impact of diabetes on treatment and outcome of STEMI patients, that was therefore the aim of the current subanalysis conducted in patients included in the International Study on Acute Coronary Syndromes-ST Elevation Myocardial Infarction (ISACS-STEMI) COVID-19. METHODS: The ISACS-STEMI COVID-19 is a retrospective registry performed in European centers with an annual volume of > 120 primary percutaneous coronary intervention (PCI) and assessed STEMI patients, treated with primary PCI during the same periods of the years 2019 versus 2020 (March and April). Main outcomes are the incidences of primary PCI, delayed treatment, and in-hospital mortality. RESULTS: A total of 6609 patients underwent primary PCI in 77 centers, located in 18 countries. Diabetes was observed in a total of 1356 patients (20.5%), with similar proportion between 2019 and 2020. During the pandemic, there was a significant reduction in primary PCI as compared to 2019, similar in both patients with (Incidence rate ratio (IRR) 0.79 (95% CI: 0.73-0.85, p < 0.0001) and without diabetes (IRR 0.81 (95% CI: 0.78-0.85, p < 0.0001) (p int = 0.40). We observed a significant heterogeneity among centers in the population with and without diabetes (p < 0.001, respectively). The heterogeneity among centers was not related to the incidence of death due to COVID-19 in both groups of patients. Interaction was observed for Hypertension (p = 0.024) only in absence of diabetes. Furthermore, the pandemic was independently associated with a significant increase in door-to-balloon and total ischemia times only among patients without diabetes, which may have contributed to the higher mortality, during the pandemic, observed in this group of patients. CONCLUSIONS: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a similar reduction in primary PCI procedures in both patients with and without diabetes. Hypertension had a significant impact on PCI reduction only among patients without diabetes. We observed a significant increase in ischemia time and door-to-balloon time mainly in absence of diabetes, that contributed to explain the increased mortality observed in this group of patients during the pandemic. TRIAL REGISTRATION NUMBER: NCT04412655.
BACKGROUND: It has been suggested the COVID pandemic may have indirectly affected the treatment and outcome of STEMI patients, by avoidance or significant delays in contacting the emergency system. No data have been reported on the impact of diabetes on treatment and outcome of STEMI patients, that was therefore the aim of the current subanalysis conducted in patients included in the International Study on Acute Coronary Syndromes-ST Elevation Myocardial Infarction (ISACS-STEMI) COVID-19. METHODS: The ISACS-STEMI COVID-19 is a retrospective registry performed in European centers with an annual volume of > 120 primary percutaneous coronary intervention (PCI) and assessed STEMI patients, treated with primary PCI during the same periods of the years 2019 versus 2020 (March and April). Main outcomes are the incidences of primary PCI, delayed treatment, and in-hospital mortality. RESULTS: A total of 6609 patients underwent primary PCI in 77 centers, located in 18 countries. Diabetes was observed in a total of 1356 patients (20.5%), with similar proportion between 2019 and 2020. During the pandemic, there was a significant reduction in primary PCI as compared to 2019, similar in both patients with (Incidence rate ratio (IRR) 0.79 (95% CI: 0.73-0.85, p < 0.0001) and without diabetes (IRR 0.81 (95% CI: 0.78-0.85, p < 0.0001) (p int = 0.40). We observed a significant heterogeneity among centers in the population with and without diabetes (p < 0.001, respectively). The heterogeneity among centers was not related to the incidence of death due to COVID-19 in both groups of patients. Interaction was observed for Hypertension (p = 0.024) only in absence of diabetes. Furthermore, the pandemic was independently associated with a significant increase in door-to-balloon and total ischemia times only among patients without diabetes, which may have contributed to the higher mortality, during the pandemic, observed in this group of patients. CONCLUSIONS: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a similar reduction in primary PCI procedures in both patients with and without diabetes. Hypertension had a significant impact on PCI reduction only among patients without diabetes. We observed a significant increase in ischemia time and door-to-balloon time mainly in absence of diabetes, that contributed to explain the increased mortality observed in this group of patients during the pandemic. TRIAL REGISTRATION NUMBER: NCT04412655.
Authors: Chor-Cheung Frankie Tam; Kent-Shek Cheung; Simon Lam; Anthony Wong; Arthur Yung; Michael Sze; Yui-Ming Lam; Carmen Chan; Tat-Chi Tsang; Matthew Tsui; Hung-Fat Tse; Chung-Wah Siu Journal: Circ Cardiovasc Qual Outcomes Date: 2020-03-17
Authors: Santiago Garcia; Mazen S Albaghdadi; Perwaiz M Meraj; Christian Schmidt; Ross Garberich; Farouc A Jaffer; Simon Dixon; Jeffrey J Rade; Mark Tannenbaum; Jenny Chambers; Paul P Huang; Timothy D Henry Journal: J Am Coll Cardiol Date: 2020-04-10 Impact factor: 24.094
Authors: Haijiang Dai; Quanyu Zhang; Arsalan Abu Much; Elad Maor; Amit Segev; Roy Beinart; Salim Adawi; Yao Lu; Nicola Luigi Bragazzi; Jianhong Wu Journal: Eur Heart J Qual Care Clin Outcomes Date: 2021-10-28
Authors: Armando Del Prete; Francesca Conway; Domenico G Della Rocca; Giuseppe Biondi-Zoccai; Francesco De Felice; Carmine Musto; Marco Picichè; Eugenio Martuscelli; Andrea Natale; Francesco Versaci Journal: Card Electrophysiol Clin Date: 2021-10-30
Authors: Giuseppe De Luca; Matteo Nardin; Magdy Algowhary; Berat Uguz; Dinaldo C Oliveira; Vladimir Ganyukov; Zan Zimbakov; Miha Cercek; Lisette Okkels Jensen; Poay Huan Loh; Lucian Calmac; Gerard Roura Ferrer; Alexandre Quadros; Marek Milewski; Fortunato Scotto di Uccio; Clemens von Birgelen; Francesco Versaci; Jurrien Ten Berg; Gianni Casella; Aaron Wong Sung Lung; Petr Kala; José Luis Díez Gil; Xavier Carrillo; Maurits Dirksen; Victor M Becerra-Munoz; Michael Kang-Yin Lee; Dafsah Arifa Juzar; Rodrigo de Moura Joaquim; Roberto Paladino; Davor Milicic; Periklis Davlouros; Nikola Bakraceski; Filippo Zilio; Luca Donazzan; Adriaan Kraaijeveld; Gennaro Galasso; Arpad Lux; Lucia Marinucci; Vincenzo Guiducci; Maurizio Menichelli; Alessandra Scoccia; Aylin Hatice Yamac; Kadir Ugur Mert; Xacobe Flores Rios; Tomas Kovarnik; Michal Kidawa; Josè Moreu; Vincent Flavien; Enrico Fabris; Iñigo Lozano Martínez-Luengas; Marco Boccalatte; Francisco Bosa Ojeda; Carlos Arellano-Serrano; Gianluca Caiazzo; Giuseppe Cirrincione; Hsien-Li Kao; Juan Sanchis Forés; Luigi Vignali; Helder Pereira; Stephane Manzo; Santiago Ordoñez; Alev Arat Özkan; Bruno Scheller; Heidi Lehtola; Rui Teles; Christos Mantis; Ylitalo Antti; João António Brum Silveira; Rodrigo Zoni; Ivan Bessonov; Stefano Savonitto; George Kochiadakis; Dimitrios Alexopulos; Carlos E Uribe; John Kanakakis; Benjamin Faurie; Gabriele Gabrielli; Alejandro Gutierrez Barrios; Juan Pablo Bachini; Alex Rocha; Frankie Chor-Cheung Tam; Alfredo Rodriguez; Antonia Anna Lukito; Veauthyelau Saint-Joy; Gustavo Pessah; Andrea Tuccillo; Giuliana Cortese; Guido Parodi; Mohammed Abed Bouraghda; Elvin Kedhi; Pablo Lamelas; Harry Suryapranata; Monica Verdoia Journal: Diabet Epidemiol Manag Date: 2021-10-30
Authors: Giuseppe De Luca; Matteo Nardin; Magdy Algowhary; Berat Uguz; Dinaldo C Oliveira; Vladimir Ganyukov; Zan Zimbakov; Miha Cercek; Lisette Okkels Jensen; Poay Huan Loh; Lucian Calmac; Gerard Roura Ferrer; Alexandre Quadros; Marek Milewski; Fortunato Scotto di Uccio; Clemens von Birgelen; Francesco Versaci; Jurrien Ten Berg; Gianni Casella; Aaron Wong Sung Lung; Petr Kala; José Luis Díez Gil; Xavier Carrillo; Maurits Dirksen; Victor M Becerra-Munoz; Michael Kang-Yin Lee; Dafsah Arifa Juzar; Rodrigo de Moura Joaquim; Roberto Paladino; Davor Milicic; Periklis Davlouros; Nikola Bakraceski; Filippo Zilio; Luca Donazzan; Adriaan Kraaijeveld; Gennaro Galasso; Arpad Lux; Lucia Marinucci; Vincenzo Guiducci; Maurizio Menichelli; Alessandra Scoccia; Aylin Hatice Yamac; Kadir Ugur Mert; Xacobe Flores Rios; Tomas Kovarnik; Michal Kidawa; Josè Moreu; Vincent Flavien; Enrico Fabris; Iñigo Lozano Martínez-Luengas; Marco Boccalatte; Francisco Bosa Ojeda; Carlos Arellano-Serrano; Gianluca Caiazzo; Giuseppe Cirrincione; Hsien-Li Kao; Juan Sanchis Forés; Luigi Vignali; Helder Pereira; Stephane Manzo; Santiago Ordoñez; Alev Arat Özkan; Bruno Scheller; Heidi Lehtola; Rui Teles; Christos Mantis; Ylitalo Antti; João A Brum Silveira; Rodrigo Zoni; Ivan Bessonov; Stefano Savonitto; George Kochiadakis; Dimitrios Alexopoulos; Carlos E Uribe; John Kanakakis; Benjamin Faurie; Gabriele Gabrielli; Alejandro Gutierrez Barrios; Juan Pablo Bachini; Alex Rocha; Frankie Chor-Cheung Tam; Alfredo Rodriguez; Antonia Anna Lukito; Veauthyelau Saint-Joy; Gustavo Pessah; Andrea Tuccillo; Giuliana Cortese; Guido Parodi; Mohamed Abed Bouraghda; Elvin Kedhi; Pablo Lamelas; Harry Suryapranata; Monica Verdoia Journal: Respir Res Date: 2022-08-15
Authors: Nitin Kapoor; Sanjay Kalra; Peter P Toth; Manfredi Rizzo; Wael Al Mahmeed; Khalid Al-Rasadi; Kamila Al-Alawi; Maciej Banach; Yajnavalka Banerjee; Antonio Ceriello; Mustafa Cesur; Francesco Cosentino; Alberto Firenze; Massimo Galia; Su-Yen Goh; Andrej Janez; Peter Kempler; Nader Lessan; Paulo Lotufo; Nikolaos Papanas; Ali A Rizvi; Amirhossein Sahebkar; Raul D Santos; Anca Pantea Stoian; Vijay Viswanathan Journal: Diabetes Ther Date: 2022-08-27 Impact factor: 3.595
Authors: Mats de Lange; Ana Sofia Carvalho; Óscar Brito Fernandes; Hester Lingsma; Niek Klazinga; Dionne Kringos Journal: Int J Environ Res Public Health Date: 2022-03-08 Impact factor: 3.390